Instrument Inactif

Communiqués NextCell Pharma AB Nasdaq Stockholm

Actions

SE0009723125

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

The paediatric diabetes study gets the green light to treat the age group 7 - 11 years	12/06	AQ
The Board of Directors and management sign in addition to subscription commitments	11/06	AQ
NextCell publishes supplement to the prospectus regarding the rights issue	10/06	AQ
Cellaviva becomes an independent company under NextCell Pharma	05/06	AQ
NextCell procures top guarantee in ongoing rights issue	04/06	AQ
The subscription period in NextCell's rights issue commences today	31/05	AQ
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million	30/05	AQ
Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years	28/05	AQ
Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)	27/05	AQ
NextCell publishes its Interim Report 2 2023/2024	25/04	AQ
Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)	24/04	AQ
The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting	24/04	AQ
NextCell's daughter company Cellaviva granted permission to handle amniotic tissue	22/04	AQ
Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons	19/04	AQ
The Swedish Medical Products Agency approves subgroup analysis in NextCell's ProTrans-Young study	27/03	AQ
NextCell establishes QVance to meet the Nordic's need for quality analytics	14/03	AQ
NextCell Pharma's updated growth strategy	27/02	AQ
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy	14/02	AQ
NextCell publishes its Interim Report 1 2023/2024	25/01	AQ
Updates regarding NextCell's Clinical Trials with ProTrans	24/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués NextCell Pharma AB Nasdaq Stockholm

Actions

SE0009723125

Communiqués

Filtres